Nevertheless, a large meta-analysis of randomised controlled trials has already demonstrated that the use of anti-TNF agents in patients with IBD showed a prevalence of neoplasia of 0.39% among the more than four thousand patients analysed, with a relative risk of cancer compared to placebo of 0.77 (95% CI 0.37–1.59), which was not statistically significant [13]. The gene discussed is TNF; the disease is inflammatory bowel disease.